AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6222700
Drug: Intralesional corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional corticosteroids (Triamcinolone acetonide at 0.63 mg/mL)
Trial: 6222700
Drug: Intralesional corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional corticosteroids (Betamethasone phosphate at 3.0, 1.5, and 0.75 mg/mL)
Trial: 19446324
Drug: Daily interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interruption of sedation with therapy as ordered by the primary care team
Trial: 6856226
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.5% bupivacaine, dilute epinephrine, and methylergonovine maleate (randomized drug regimens)
Trial: 23550422
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg and extended release nicotinic acid 1G
Trial: 18381377
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of bone marrow mononuclear cells (BMC)
Trial: 29923955
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (control group)
Trial: 17027571
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg/day)
Trial: 12792352
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with stavudine and/or protease inhibitor
Trial: 1515247
Drug: Alizapride 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride 2.5 mg/kg four times daily on days 2-5 plus dexamethasone as in group C
Trial: 1515247
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5
Trial: 30529387
Drug: Sorafenib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib + concurrent transarterial chemoembolization (cTACE)
Trial: 8842603
Drug: Glimepiride 8
RxNorm normalized name: glimepiride 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 8 mg
Trial: 11572297
Drug: Compomer/hybrid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compomer/hybrid combination
Trial: 11572297
Drug: Flowable/hybrid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flowable/hybrid combination
Trial: 7933494
Drug: Hypertonic lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic lactated Ringer's solution (HLS) with sodium of 213 mEq.l‐1
Trial: 7933494
Drug: Regular lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular lactated Ringer's solution (control)
Trial: 3230151
Drug: Immediate-release verapamil
RxNorm normalized name: verapamil Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release verapamil (80 to 120 mg three times a day)
Trial: 3230151
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil (240 mg daily)
Trial: 30630788
Drug: Routine western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine western drug therapy
Trial: 31416769
Drug: Riociguat (0.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (0.5-2.5 mg three times daily)
Trial: 23902840
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 320 µg/day plus formoterol 9 µg/day
Trial: 20196184
Drug: Long-term lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term lithium treatment
Trial: 14608586
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of different strategies in a multi-level approach
Trial: 11307438
Drug: One-visit root
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit root canal treatment without calcium hydroxide dressing.
Trial: 9305334
Drug: Gabapentin 3,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 3,600 mg/d
Trial: 3830245
Drug: Caffeine (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (oral, 5.83 mg X kg‐1 lean body weight)
Trial: 31739991
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day and Bevacizumab 10 mg/kg every 14 days on a 28-day cycle
Trial: 17256446
Drug: Erdosteine with
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine with amoxicillin
Trial: 17256446
Drug: Amoxicillin-placebo combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-placebo combination
Trial: 26422093
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg (for children > 20 kg)
Trial: 17327934
Drug: Esomeprazole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (all doses)
Trial: 23274592
Drug: Astaxanthin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (20 mg per day for 4 weeks)
Trial: 21482348
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (LMWH) dalteparin 5000 IU once daily
Trial: 21482348
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) 5000 IU subcutaneous injection
Trial: 15019387
Drug: Superomedial retrobulbar
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Superomedial retrobulbar injection
Trial: 21215828
Drug: DTaP and
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP and IPV vaccines (separate administration)
Trial: 17958944
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (once-weekly)
Trial: 12484708
Drug: Echinacea (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea (1-g doses six times on the first day and three times on each subsequent day for a maximum of 10 days)
Trial: 9932945
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of regular-release levodopa (rr-L-dopa) and sustained-release levodopa (sr-L-dopa)
Trial: 7474027
Drug: Daily acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily acupuncture in three auricular sites plus one body site (LI-4)
Trial: 375733
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy with Nonoxynol 9
Trial: 30836166
Drug: 78 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 78 Gy in 39 fractions of photon radiation therapy
Trial: 30836166
Drug: 70 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 Gy in 35 fractions of photon radiation therapy
Trial: 24285599
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g fish oil/day (540 mg eicosapentaenoic acid + 360 mg docosahexaenoic acid)
Trial: 26251920
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g soy oil/day (placebo)
Trial: 22990031
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate supplementation (1000 mg Ca/d, 5 d/wk) for 12 months
Trial: 20149038
Drug: Acute oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral hydration
Trial: 17316154
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa administered weekly, every 2 weeks, and every 3 weeks
Trial: 17316154
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (weight-based and fixed dosing)
Trial: 17316154
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa at extended dosing intervals of at least 3 weeks
Trial: 11579362
Drug: Candesartan and
RxNorm normalized name: candesartan and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan and Enalapril combination
Trial: 9833602
Drug: Frusemide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide administered at a constant-rate intravenous infusion for 10 min
Trial: 9833602
Drug: Frusemide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide administered at a constant-rate intravenous infusion for 30 min
Trial: 30231173
Drug: 1% HA
RxNorm normalized name: TheraSeal 1% Hand Protection Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% HA gel
Trial: 20693270
Drug: SCH351125 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH351125 (oral CCR5 inhibitor)
Trial: 10648312
Drug: Dimenhydrinate suppositories
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate suppositories
Trial: 8382708
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg tirilazad mesylate
Trial: 8382708
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg tirilazad mesylate
Trial: 8382708
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg tirilazad mesylate
Trial: 8382708
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg tirilazad mesylate
Trial: 2876337
Drug: Aspirin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin sensitivity
Trial: 30594335
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy including neurodynamic techniques (MT).
Trial: 30594335
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG; without therapy).
Trial: 23890962
Drug: Endoscopic thyroidectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic thyroidectomy using the oral vestibular approach (ETOVA)
Trial: 12492610
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (8 mg once a day)
Trial: 3028456
Drug: Frusemide 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 80 mg
Trial: 22822928
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of flurbiprofen (40 mg administered twice at 16 and 2 hours before surgery)
Trial: 15117238
Drug: 0.2% GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% GTN gel twice a day for a minimum of 6 weeks
Trial: 11284826
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ondansetron
Trial: 3285630
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of etretinate and PUVA
Trial: 29607842
Drug: Platelet-rich fibrin
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich fibrin gel
Trial: 21075366
Drug: Adjusted thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted thermal dose based on ovarian volume (60 J/cm³ of ovarian tissue)
Trial: 21075366
Drug: Fixed thermal
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed thermal dosage (600 J per ovary)
Trial: 7701222
Drug: Caldwell-Luc (C-L)
RxNorm normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caldwell-Luc (C-L) procedure
Trial: 1619991
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) administration (12 IU/d subcutaneously)
Trial: 29595123
Drug: Salbutamol 4
RxNorm normalized name: Salbutamol 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 4 mg
Trial: 30382016
Drug: Adjunctive rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive rifampicin (600-900 mg/day, oral or intravenous) for 14 days
Trial: 28078869
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy laser therapy (HELT) at 650 nm
Trial: 11437176
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg/d)
Trial: 28304313
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy offered once weekly for 16 weeks
Trial: 28304313
Drug: Group recreational
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group recreational therapy
Trial: 25887806
Drug: Triple Antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple Antibiotic Paste (TAP) at 1000 mg/mL
Trial: 25887806
Drug: Triple Antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple Antibiotic Paste (TAP) at 0.5 mg/mL
Trial: 25887806
Drug: Double Antibiotic
RxNorm normalized name: Double Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double Antibiotic Paste (DAP) at 0.5 mg/mL
Trial: 24195278
Drug: Chloramine T
RxNorm normalized name: chloramine t
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramine T (2 mg/l)
Trial: 24195278
Drug: Peracetic acid
RxNorm normalized name: PERACETIC ACID
DrugBank: Peracetic acid (DB14556)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peracetic acid (45 microl/l)
Trial: 15894097
Drug: Tamoxifen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (5 years) following anthracycline-based chemotherapy
Trial: 15894097
Drug: Anthracycline-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-based chemotherapy followed by tamoxifen
Trial: 7840379
Drug: Nutrient hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrient hepatic blood flow > 325 mL/min
Trial: 623129
Drug: Other antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antibiotics due to specific indications or counterindications
Trial: 25631485
Drug: 0.1% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% sodium hyaluronate ophthalmic solution (HA)
Trial: 23883675
Drug: Ad libitum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad libitum high-fiber, low-fat diet and daily exercise (2-2.5 h)
Trial: 15089811
Drug: FTY720 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 (1 mg oral dose) under fasting conditions
Trial: 15089811
Drug: FTY720 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 (1 mg oral dose) after a high fat meal
Trial: 11575286
Drug: Leuprolide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide and pamidronate (60 mg intravenously every 12 weeks)
Trial: 3754233
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg bd
Trial: 9600792
Drug: Ibandronate treatment
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate treatment
Trial: 20716738
Drug: Gentamicin-collagen sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin-collagen sponge (2 sponges, total gentamicin of 260 mg)
Trial: 18085275
Drug: LDIH (60-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDIH (60-minute daily exposures to normobaric 12% O2)
Trial: 10367219
Drug: Aspirin (asa)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (asa) 160 mg/die plus low-intensity oral anticoagulation (target INR: 1.5-2.5)
Trial: 10367219
Drug: Picotamide (pico)
RxNorm normalized name: picotamide
DrugBank: Picotamide (DB13327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (pico) 300 mg/tid plus low-intensity oral anticoagulation
Trial: 2188797
Drug: Intramuscular flupenthixol
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular flupenthixol decanoate (5 to 10 mg/fortnight)
Trial: 2188797
Drug: Oral amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amitriptyline (75 to 150 mg/day)
Trial: 24261310
Drug: Preventive laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive laser therapy (red or infrared) for 5 days starting on the 1st day of infusion
Trial: 24261310
Drug: Therapeutic laser
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic laser therapy (red or infrared) only if mucositis developed
Trial: 17298645
Drug: Minnesota day
RxNorm normalized name: influenza A virus A/Minnesota/41/2019 (H3N2) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minnesota day clinic treatment
Trial: 17298645
Drug: Public out‐patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Public out‐patient alcohol clinic treatment
Trial: 10633536
Drug: Lying posture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lying posture (L) for 20 min
Trial: 3893128
Drug: 135 mEq/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mEq/l sodium dialysate
Trial: 3893128
Drug: 143 mEq/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 143 mEq/l sodium dialysate
Trial: 26324250
Drug: Nicotine concentration
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine concentration of 8 mg/mL
Trial: 22464410
Drug: OC (2
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OC (2 mg chlormadinone acetate/30 mcg ethinylestradiol)
Trial: 11939435
Drug: Isoprenaline (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (both doses)
Trial: 20716712
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (2 g/day)
Trial: 15807876
Drug: GH 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 0.1 IU/kg/day [0.033 mg/kg/day]
Trial: 8874372
Drug: Glipizide (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (maximum daily dosage)
Trial: 8874372
Drug: Glyburide (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (maximum daily dosage)
Trial: 8874372
Drug: First-generation sulfonylurea
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation sulfonylurea agents
Trial: 1172599
Drug: beta‐acetyldigoxin in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐acetyldigoxin in alcoholic solution
Trial: 4850376
Drug: digoxin solution
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: digoxin solution
Trial: 12436805
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) - ten sessions
Trial: 12436805
Drug: Fluoxetine -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine - 20 mg daily
Trial: 12436805
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (CBT plus fluoxetine)
Trial: 10359466
Drug: Psychodynamic-interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic-interpersonal psychotherapy (8 weekly sessions)
Trial: 8537197
Drug: 0.2 mg/ml
RxNorm normalized name: iodine 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/ml of Mitomycin C (MMC)
Trial: 31148988
Drug: Fenugreek 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek 2 g/day
Trial: 31148988
Drug: Glibenclamide 5
RxNorm normalized name: glibenclamide 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 5 mg once daily
Trial: 28277854
Drug: Mepolizumab 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 75 mg intravenous (IV)
Trial: 29949045
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg subcutaneous (SC)
Trial: 26621118
Drug: XM17 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XM17 (300 IU subcutaneous)